These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 34009708)

  • 1. Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis.
    Mann JFE; Buse JB; Idorn T; Leiter LA; Pratley RE; Rasmussen S; Vilsbøll T; Wolthers B; Perkovic V
    Diabetes Obes Metab; 2021 Sep; 23(9):2058-2066. PubMed ID: 34009708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER.
    Shaman AM; Bain SC; Bakris GL; Buse JB; Idorn T; Mahaffey KW; Mann JFE; Nauck MA; Rasmussen S; Rossing P; Wolthers B; Zinman B; Perkovic V
    Circulation; 2022 Feb; 145(8):575-585. PubMed ID: 34903039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.
    Verma S; McGuire DK; Bain SC; Bhatt DL; Leiter LA; Mazer CD; Monk Fries T; Pratley RE; Rasmussen S; Vrazic H; Zinman B; Buse JB
    Diabetes Obes Metab; 2020 Dec; 22(12):2487-2492. PubMed ID: 32744418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial.
    Buse JB; Bain SC; Mann JFE; Nauck MA; Nissen SE; Pocock S; Poulter NR; Pratley RE; Linder M; Monk Fries T; Ørsted DD; Zinman B;
    Diabetes Care; 2020 Jul; 43(7):1546-1552. PubMed ID: 32366578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.
    Leiter LA; Bain SC; Bhatt DL; Buse JB; Mazer CD; Pratley RE; Rasmussen S; Ripa MS; Vrazic H; Verma S
    Diabetes Obes Metab; 2020 Sep; 22(9):1690-1695. PubMed ID: 32372454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.
    Mann JFE; Fonseca V; Mosenzon O; Raz I; Goldman B; Idorn T; von Scholten BJ; Poulter NR
    Circulation; 2018 Dec; 138(25):2908-2918. PubMed ID: 30566006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
    Wright EE; Aroda VR
    Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular safety and benefits of GLP-1 receptor agonists.
    Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Kristensen SL; Rørth R; Jhund PS; Docherty KF; Sattar N; Preiss D; Køber L; Petrie MC; McMurray JJV
    Lancet Diabetes Endocrinol; 2019 Oct; 7(10):776-785. PubMed ID: 31422062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events.
    Lingvay I; Hansen T; Macura S; Marre M; Nauck MA; de la Rosa R; Woo V; Yildirim E; Wilding J
    BMJ Open Diabetes Res Care; 2020 Oct; 8(2):. PubMed ID: 33115821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
    Sloan LA
    J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.
    Sun F; Wu S; Guo S; Yu K; Yang Z; Li L; Zhang Y; Quan X; Ji L; Zhan S
    Diabetes Res Clin Pract; 2015 Oct; 110(1):26-37. PubMed ID: 26358202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials.
    Mann JFE; Hansen T; Idorn T; Leiter LA; Marso SP; Rossing P; Seufert J; Tadayon S; Vilsbøll T
    Lancet Diabetes Endocrinol; 2020 Nov; 8(11):880-893. PubMed ID: 32971040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.
    Rossing P; Baeres FMM; Bakris G; Bosch-Traberg H; Gislum M; Gough SCL; Idorn T; Lawson J; Mahaffey KW; Mann JFE; Mersebach H; Perkovic V; Tuttle K; Pratley R
    Nephrol Dial Transplant; 2023 Aug; 38(9):2041-2051. PubMed ID: 36651820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio.
    Kaneko M; Narukawa M
    Ann Pharmacother; 2018 Jul; 52(7):632-638. PubMed ID: 29424239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of liraglutide on renal function: A randomized clinical trial.
    von Scholten BJ; Persson F; Rosenlund S; Hovind P; Faber J; Hansen TW; Rossing P
    Diabetes Obes Metab; 2017 Feb; 19(2):239-247. PubMed ID: 27753201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis.
    Rossing P; Bain SC; Bosch-Traberg H; Sokareva E; Heerspink HJL; Rasmussen S; Mellbin LG
    Cardiovasc Diabetol; 2023 Aug; 22(1):220. PubMed ID: 37620807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide and Renal Outcomes in Type 2 Diabetes.
    Mann JFE; Ørsted DD; Brown-Frandsen K; Marso SP; Poulter NR; Rasmussen S; Tornøe K; Zinman B; Buse JB;
    N Engl J Med; 2017 Aug; 377(9):839-848. PubMed ID: 28854085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.